RECURRENT MENINGIOMA
Clinical trials for RECURRENT MENINGIOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MENINGIOMA trials appear
Sign up with your email to follow new studies for RECURRENT MENINGIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Hard-to-Treat brain tumors: targeted radiation trial launches
Disease control Recruiting nowThis study tests a drug called 177Lu-DOTATATE for people with recurrent meningioma, a type of brain tumor that has come back after surgery or radiation. The drug delivers radiation directly to tumor cells that have a specific marker (SSTR). About 136 adults will be randomly assig…
Matched conditions: RECURRENT MENINGIOMA
Phase: PHASE2 • Sponsor: European Organisation for Research and Treatment of Cancer - EORTC • Aim: Disease control
Last updated May 17, 2026 06:51 UTC
-
New hope for brain tumor patients: targeted drugs aim to halt meningioma growth
Disease control Recruiting nowThis study tests four targeted drugs (vismodegib, GSK2256098, capivasertib, and abemaciclib) in people with progressive meningiomas that have specific gene mutations. The goal is to see if these drugs can stop or slow tumor growth. About 124 adults with recurrent or worsening men…
Matched conditions: RECURRENT MENINGIOMA
Phase: PHASE2 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New hope for brain tumor patients: radioactive drug targets tough meningiomas
Disease control Recruiting nowThis study tests a radioactive drug called Lutathera for people with a type of brain tumor (meningioma) that cannot be surgically removed and has continued to grow after radiation therapy. The drug is given through a vein and aims to kill tumor cells. The goal is to see if it can…
Matched conditions: RECURRENT MENINGIOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 11, 2026 20:49 UTC